Ascension St John Hospital
- Type
- Teaching hospital
- Where
- Chicago, IL
- Medicare CCN
- 230165
- Received
- $289,502 in 45 records, 2025 ($24,420 general, $265,082 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 16 | $24,420 |
| 2025 | Research payment | 29 | $265,082 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | 1 | $120,006 | 2025 |
| PFIZER INC. | 11 | $94,270 | 2025 |
| Medtronic, Inc. | 14 | $20,089 | 2025 |
| Genentech, Inc. | 1 | $19,076 | 2025 |
| BeOne Medicines USA, Inc. | 1 | $8,750 | 2025 |
| Parkedale Pharmaceuticals, Inc. | 5 | $4,960 | 2025 |
| ABBVIE INC. | 2 | $4,000 | 2025 |
| Olympus Corporation of the Americas | 1 | $4,000 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $4,000 | 2025 |
| ERBE USA Inc | 1 | $2,000 | 2025 |
| GENZYME CORPORATION | 1 | $2,000 | 2025 |
| Gilead Sciences, Inc. | 1 | $2,000 | 2025 |
| Olympus America Inc. | 2 | $2,000 | 2025 |
| Siemens Medical Solutions USA, Inc. | 1 | $1,800 | 2025 |
| Abbott Laboratories | 1 | $550 | 2025 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 29 | $265,082 |
| Space rental or facility fees (teaching hospital only) | 9 | $14,550 |
| Grant | 1 | $4,000 |
| Education | 1 | $2,000 |
| Debt forgiveness | 1 | $1,800 |
| Consulting Fee | 3 | $1,075 |
| Royalty or License | 1 | $995 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-11 | PFIZER INC. | $6,846 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2025 | |
| 2025-12-11 | Medtronic, Inc. | $831 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2025 |
| 2025-12-11 | Medtronic, Inc. | $831 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2025 |
| 2025-12-09 | BeOne Medicines USA, Inc. | $8,750 | Research payment | Cash or cash equivalent | BRUKINSA Drug, Oncology | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidom | 2025 |
| 2025-11-26 | PFIZER INC. | $3,876 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2025 | |
| 2025-11-03 | Parkedale Pharmaceuticals, Inc. | $350 | Consulting Fee | Cash or cash equivalent | BICILLIN CR Drug, INFECTIOUS DISEASES | 2025 | |
| 2025-10-27 | Parkedale Pharmaceuticals, Inc. | $605 | Consulting Fee | Cash or cash equivalent | BICILLIN CR Drug, INFECTIOUS DISEASES | 2025 | |
| 2025-10-14 | Parkedale Pharmaceuticals, Inc. | $120 | Consulting Fee | Cash or cash equivalent | BICILLIN CR Drug, INFECTIOUS DISEASES | 2025 | |
| 2025-09-29 | Parkedale Pharmaceuticals, Inc. | $2,890 | Research payment | Cash or cash equivalent | BICILLIN CR Drug, INFECTIOUS DISEASES | PRE CLINICAL | 2025 |
| 2025-09-03 | Medtronic, Inc. | $2,491 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2025 |
| 2025-09-03 | Medtronic, Inc. | $2,491 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2025 |
| 2025-08-25 | Parkedale Pharmaceuticals, Inc. | $995 | Royalty or License | Cash or cash equivalent | BICILLIN CR Drug, INFECTIOUS DISEASES | 2025 | |
| 2025-06-26 | PFIZER INC. | $9,994 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCI | 2025 | |
| 2025-06-23 | Medtronic, Inc. | $4,192 | Research payment | Cash or cash equivalent | SYMPLICITY G3 Device, Renal Denervation System | SPYRAL AFFIRM | 2025 |
| 2025-06-05 | Medtronic, Inc. | $745 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2025 |
| 2025-06-05 | Medtronic, Inc. | $745 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2025 |
| 2025-05-28 | PFIZER INC. | $565 | Research payment | Cash or cash equivalent | AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL | 2025 | |
| 2025-05-21 | AstraZeneca Pharmaceuticals LP | $120,006 | Research payment | Cash or cash equivalent | Truqap Drug, Oncology | Capivasertib plus Palbociclib plus Fulvestrant for HR/HER2 Advanced Breast Cancer CAPItello 292. | 2025 |
| 2025-05-16 | Medtronic, Inc. | $89 | Research payment | In-kind items and services | SYMPLICITY G3 Device, Renal Denervation System | SPYRAL AFFIRM | 2025 |
| 2025-05-14 | PFIZER INC. | $565 | Research payment | Cash or cash equivalent | AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL | 2025 | |
| 2025-05-10 | PFIZER INC. | $17,462 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-04-25 | PFIZER INC. | $2,175 | Research payment | Cash or cash equivalent | AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL | 2025 | |
| 2025-04-24 | Medtronic, Inc. | $1,067 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2025 |
| 2025-04-24 | Medtronic, Inc. | $1,067 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2025 |
| 2025-04-23 | Medtronic, Inc. | $180 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2025 |
| 2025-04-23 | Medtronic, Inc. | $180 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2025 |
| 2025-04-14 | Olympus Corporation of the Americas | $4,000 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-04-12 | GENZYME CORPORATION | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-04-12 | ERBE USA Inc | $2,000 | Education | Cash or cash equivalent | Erbe VIO3, Erbe Jet Device, gastroenterology | 2025 | |
| 2025-04-02 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-04-01 | Olympus America Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Single Use Repositionable Clip Device, Endotherapy | 2025 | |
| 2025-04-01 | Olympus America Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Single Use Repositionable Clip Device, Endotherapy | 2025 | |
| 2025-03-29 | PFIZER INC. | $10,487 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-03-28 | ABBVIE INC. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-03-28 | Abbott Laboratories | $550 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-03-25 | ABBVIE INC. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CREON Drug, ENDOCRINOLOGY | 2025 | |
| 2025-03-24 | Genentech, Inc. | $19,076 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | Phase 3 randomized mosunetuzumab with polatuzumab in comparison with R GemOx in R R NHL | 2025 |
| 2025-03-20 | Medtronic, Inc. | $3,429 | Research payment | Cash or cash equivalent | SYMPLICITY G3 Device, Renal Denervation System | SPYRAL AFFIRM | 2025 |
| 2025-03-12 | Gilead Sciences, Inc. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Epclusa Drug, HCV | 2025 | |
| 2025-03-04 | PFIZER INC. | $15,933 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-02-21 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-02-06 | PFIZER INC. | $9,070 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-01-28 | PFIZER INC. | $17,292 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-01-27 | Medtronic, Inc. | $1,750 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | Optimize Pro | 2025 |
| 2025-01-10 | Siemens Medical Solutions USA, Inc. | $1,800 | Debt forgiveness | Cash or cash equivalent | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Chicago, IL, county Cook County, IL, state Illinois; placed by its city name.
| Measure | Place (city or town) Chicago, IL | County Cook County, IL | State Illinois |
|---|---|---|---|
| Population B01003 | 2,711,226 | 5,182,090 | 12,694,798 |
| Population, 2020 census P1 | 2,746,388 | 5,275,541 | 12,812,508 |
| Median age B01002 | 35.8 | 38.0 | 39.0 |
| Under 18 B01001 | 19.4% | 21.1% | 21.8% |
| 65 and over B01001 | 13.8% | 16.0% | 17.0% |
| Households B11001 | 1,160,205 | 2,100,230 | 5,036,449 |
| Foreign born B05002 | 20.9% | 21.7% | 14.7% |
| Median household income B19013 | $77,902 | $83,498 | $83,390 |
| Median family income B19113 | $95,774 | $104,836 | $106,018 |
| Per capita income B19301 | $50,086 | $49,329 | $46,406 |
| Poverty rate B17001 | 16.8% | 13.5% | 11.8% |
| Unemployment rate B23025 | 8.0% | 7.0% | 5.8% |
| Civilian labor force B23025 | 1,517,330 | 2,792,888 | 6,652,134 |
| Mean commute (minutes) B08013 | 33.1 | 31.5 | 27.8 |
| Bachelor's degree or higher B15003 | 44.3% | 42.7% | 37.8% |
| Housing units B25001 | 1,277,054 | 2,276,493 | 5,457,452 |
| Owner-occupied B25003 | 46.0% | 57.7% | 67.1% |
| Renters B25003 | 54.0% | 42.3% | 32.9% |
| Median home value B25077 | $334,100 | $324,500 | $263,300 |
| Median gross rent B25064 | $1,440 | $1,435 | $1,274 |
| White, not Hispanic B03002 | 32.1% | 40.1% | 58.1% |
| Black B03002 | 27.4% | 21.8% | 13.3% |
| Hispanic or Latino B03002 | 29.7% | 26.8% | 18.8% |
| Asian B03002 | 7.2% | 7.9% | 5.9% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 4.6% in Sep 2026 (4.5% a year earlier); per capita personal income $78,987 in 2025, up 28% in five years (+3.1% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Chicago, IL.
Comments